Alone, these mutations display a modest effect; however the coexistence of BRAF V600E and TERTp mutations is associated with a higher cancer aggressiveness, which is reflected by lymph node metastases, distant metastases, advanced tumor stage, recurrence, and even disease-specific mortality of PTC patients [20,21]. This evidence concerns the gene BRAF and cancer.